NCT01223235

Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab

A PILOT STUDY OF A POLYVALENT VACCINE-KLH CONJUGATE + OPT-821 GIVEN IN COMBINATION WITH BEVACIZUMAB IN PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN SECOND OR GREATER COMPLETE OR PARTIAL CLINICAL REMISSION

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The immune system of the body has the ability to fight and eliminate infections and cancers. Immune treatments, such as in this study, seek to teach the immune system to find and destroy cancer cells. The purpose of this study is to test whether it is safe to treat the cancer with a vaccine and another drug called bevacizumab (also known as Avastin).

Conditions

• Fallopian Tubes Cancer
• Ovarian Cancer
• Peritoneal Cancer

Interventions

Type	Name	Description
BIOLOGICAL	bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821	A maximum of 6 doses of the polyvalent-KLH vaccine and OPT-821 will be administered to each patient as per the schedule. Bevacizumab will be administered once every two weeks until week 11 and then once every three weeks according to the schedule. When the 6 vaccinations of the polyvalent-KLH vaccine +OPT821 are completed, patients may still continue to receive bevacizumab on the once every three week schedule.

Timeline

• Start date: 2010-10-01
• Primary completion: 2017-09-01
• Completion: 2017-09-01
• First posted: 2010-10-18
• Last updated: 2018-06-12
• Results posted: 2018-05-14

Locations

1 site across 1 country: United States